e-learning
resources
ERJ
2007
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Daily versus weekly azithromycin in cystic fibrosis patients
McCormack J., Bell S., Senini S., Walmsley K., Patel K., Wainwright C., Serisier D., Harris M., Bowler S.
Source:
Eur Respir J 2007; 30: 487-495
Journal Issue:
September
Disease area:
Paediatric lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
McCormack J., Bell S., Senini S., Walmsley K., Patel K., Wainwright C., Serisier D., Harris M., Bowler S.. Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J 2007; 30: 487-495
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
Source: Eur Respir J 2002; 20: 658-664
Year: 2002
Once-daily tobramycin in the treatment of adult patients with cystic fibrosis
Source: Eur Respir J 2002; 19: 303-309
Year: 2002
Efficacy of ciprofloxacin against resistant mucoid or non-mucoid
P. aeruginosa
isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis},
Source: Eur Respir J 2012; 40: 1014-1023
Year: 2012
Acquired resistance to macrolides in
Pseudomonas aeruginosa
from cystic fibrosis patients
Source: Eur Respir J, 49 (5) 1601847; 10.1183/13993003.01847-2016
Year: 2017
Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and
Pseudomonas aeruginosa
infection
Source: Eur Respir J 2005; 26: Suppl. 49, 620s
Year: 2005
Fosfomycin for pseudomonas related exacerbations of cystic fibrosis
Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools
Year: 2008
Azithromycin in chronic respiratory infections with
pseudomonas aeruginosa
in patients without cystic fibrosis
Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host
Year: 2008
Chronic use of azithromycin in CF is associated with a substantial increase in macrolide resistance of
S. aureus
and
haemophilus
Source: Annual Congress 2006 - Cystic fibrosis lung disease: molecules images and drugs
Year: 2006
Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre
Source: Eur Respir J 2006; 27: 937-943
Year: 2006
Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort
Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives
Year: 2015
Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients
Source: Eur Respir J 2002; 20: Suppl. 38, 379s
Year: 2002
Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA)
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015
Nebulized antibiotics in patients with non-cystic fibrosis bronchiectasis ans chronic pseudomonas aeruginosa infection
Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis
Year: 2011
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
Source: Eur Respir J 2013; 41: 1107-1115
Year: 2013
Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa
Source: Eur Respir J 2003; 22: 503-506
Year: 2003
Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016
Susceptibility of problem respiratory pathogens to levofloxacin in cystic fibrosis (CF)
Source: Eur Respir J 2002; 20: Suppl. 38, 526s
Year: 2002
Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic
P. aeruginosa
airway colonization
Source: Eur Respir J 2003; 22: Suppl. 45, 514s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept